Navigation Links
QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics
Date:5/26/2010

    GERMANTOWN, Maryland and HILDEN, Germany, May 26, 2010
/PRNewswire-FirstCall/ -- QIAGEN N.V. (NASDAQ: QGEN [
http://quotes.nasdaq.com/asp/SummaryQuote.asp?symbol=QGEN&selected=QGEN ];
Frankfurt, Prime Standard: QIA [
http://www.boerse-frankfurt.de/DE/index.aspx?pageID=35&ISIN=NL0000240000 ])
today announced that it has signed an agreement with Roche Molecular Systems
Inc., a unit of Roche Holding AG (ROG.VX [
http://www.reuters.com/finance/stocks/overview?symbol=ROG.VX ]), resolving a
dispute over distribution rights for a set of companion diagnostic products
developed and manufactured by QIAGEN's Manchester subsidiary DxS Ltd.
Subsequently, the parties withdrew their claims filed against one another in
the action that was pending in the US District Court for the Southern
District of New York.

Under the terms of the agreement, Roche maintained its rights to distribute the two assays it currently distributes (KRAS and EGFR) under the DxS TheraScreen(R) label and, under certain conditions, to distribute future versions thereof. QIAGEN obtained rights to distribute these assays under the QIAGEN label and also obtained exclusive distribution rights for all other assays, including future assays, developed and manufactured at QIAGEN's Manchester subsidiary. QIAGEN intends to use the QIAGEN TheraScreen(R) label for the assays it distributes. QIAGEN also granted Roche the option to extend the term of the distribution agreement for one of the assays, the TheraScreen(R) EGFR assay, beyond the term of this agreement which ends in 2011.

"We are pleased to have reached this agreement with Roche", said Peer Schatz, CEO of QIAGEN. "The agreement provides a clear distribution plan for QIAGEN's pioneering TheraScreen(R) companion diagnostics. Companion diagnostics help physicians to customize therapies, greatly reduce healthcare costs and prevent harmful treatments for patients suffering from serious diseases."

"We are pleased to maintain our distribution agreement and to continue to provide access to DxS TheraScreen companion diagnostics that have the potential to improve cancer patient care," said Paul Brown, Ph.D., President and CEO of Roche Molecular Systems.

Background:

Personalized healthcare approaches are based on patients' molecular profiles and already play an increasingly important role for the treatment of cardiovascular and neurological diseases and - most prominently - cancer. The number of molecular markers for various therapies and indications has been increasing steadily. Today, there are already 32 genomic biomarkers identified by FDA in the context of FDA-approved drug labels. In the last ten years the market for personalized healthcare drugs exceeded US$ 13 billion, reflecting a CAGR of 24%.

About QIAGEN

QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated bio-molecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. QIAGEN employs more than 3,500 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80,000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: http://www.roche.com.

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the applied testing markets, clinical research markets and proteomics markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products (including fluctuations due to the level and timing of customers' funding, budgets, and other factors), our ability to obtain regulatory approval of our infectious disease panels, difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors' products, market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

    Contacts:

    Investor Relations QIAGEN:

    Dr. Solveigh Mahler
    Director Investor Relations
    QIAGEN N.V.
    +49-2103-29-11710
    e-mail: solveigh.maehler@qiagen.com

    Albert F. Fleury
    Investor Relations North America
    QIAGEN N.V.
    +1-301-944-7028
    e-mail: albert.fleury@qiagen.com

    Public Relations QIAGEN:

    Dr. Thomas Theuringer
    Director Public Relations
    QIAGEN GmbH
    +49-2103-29-11826
    email: thomas.theuringer@qiagen.com

    For US Media, Roche Molecular Systems:

    Karin Bauer
    Corporate Communications
    Roche Molecular Systems
    Pleasanton, California
    +1-925-730-8114
    email: karin.bauer.kb2@roche.com

    For EU Media, Roche:

    Claudia Schmitt
    Corporate Communications
    Roche
    Basel, Switzerland
    +41-61-688-8888
    claudia.schmitt.cs2@roche.com



'/>"/>
SOURCE Qiagen
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests
2. QIAGEN Acquires Exclusive Licence for Key PI3K gene
3. QIAGENs New Product Line, QIAsafe(R) DNA Blood, has Been Co-Developed With Biomatrica and is Based on Biomatricas SampleMatrix(R) Technology
4. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Second Quarter 2009 Financial Results Call Set for August 11
5. Plexus Awarded Development Contract With QIAGEN
6. QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata
7. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Fourth Quarter and Year-End 2008 Financial Results Call Set for February 10
8. QIAGEN Welcomes 3,000th Employee in 20th year of U.S. Operations
9. SciQuest Announces Strategic Alliance with QIAGEN
10. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Second Quarter 2008 Financial Results Call Set for August 5
11. Webcast Alert: QIAGEN N.V. Announces First Quarter 2008 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... , June 28, 2017  Scientific Analytics, Inc.,s DARI ... showcased in front of thousands of healthcare providers at Premier ... 27.   Scientific Analytics, DARI Motion Health was debuted ... recognizes advances in healthcare while highlighting industry suppliers committed to ... ...
(Date:6/28/2017)... , ... June 28, 2017 , ... ... international market with three research projects accepted for presentation at the 33rd Annual ... Nearly 10,000 participants – including some of the world’s top thought leaders in ...
(Date:6/28/2017)... ... ... Studies indicate that replacing damaged brain cells with those derived from human ... has not been determined is the optimal stage during differentiation of the stem cells ... study coming out of Singapore, recently published in STEM CELLS Translational Medicine journal may ...
(Date:6/27/2017)... ... 2017 , ... According to a recent report from the ... have negative short- or long-term effects on benthic communities. , The ESTCP ... at the Puget Sound Naval Shipyard & Intermediate Maintenance Facility in Bremerton, Washing. ...
Breaking Biology Technology:
(Date:4/5/2017)... NEW YORK , April 5, 2017 ... security, is announcing that the server component of the ... is known for providing the end-to-end security architecture that ... customers. HYPR has already secured over 15 ... system makers including manufacturers of connected home product suites ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
(Date:3/30/2017)... -- On April 6-7, 2017, Sequencing.com will host the world,s ... at Microsoft,s headquarters in Redmond, Washington ... health and wellness apps that provide a unique, personalized ... is the first hackathon for personal genomics and the ... the genomics, tech and health industries are sending teams ...
Breaking Biology News(10 mins):